Surgeons Back Preoperative Chemotherapy for Intrahepatic Cholangiocarcinoma Management

An international survey reveals that 91.6% of surgeons advocate for preoperative chemotherapy in initially unresectable intrahepatic cholangiocarcinoma (ICCA). Most cite tumor downstaging and selecting favorable cases for R0 resection as major benefits. Key concerns defining unresectability include insufficient future liver remnant volume and inability to achieve negative margins. As multidisciplinary discussions dominate decisions, establishing expert consensus on ICCA management may enhance treatment pathways and patient outcomes.